Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | HTR6 | P50406 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4159670 | 1.00 | CYP2D6 (0.33) | CYP2D6MEN1KMT2ALMNAL3MBTL3 | |
| SCHEMBL206436 | 0.98 | CYP2D6 (0.32) | CYP2D6MEN1KMT2ALMNAL3MBTL3 | |
| SCHEMBL204532 | 0.98 | CYP2D6 (0.32) | CYP2D6MEN1KMT2ALMNAL3MBTL3 | |
| SCHEMBL735235 | 0.95 | CYP2D6 (0.33) | CYP2D6MEN1KMT2ALMNAL3MBTL3 | |
| SCHEMBL736026 | 0.93 | CYP2D6 (0.32) | CYP2D6MEN1KMT2ALMNAL3MBTL3 | |
| SCHEMBL737923 | 0.93 | CYP2D6 (0.32) | CYP2D6MEN1KMT2ALMNAL3MBTL3 | |
| SCHEMBL739014 | 0.93 | CYP2D6 (0.32) | CYP2D6MEN1KMT2ALMNAL3MBTL3 | |
| SCHEMBL736908 | 0.92 | L3MBTL3 (0.32) | CYP2D6MEN1KMT2ALMNAL3MBTL3 | |
| SCHEMBL9469528 | 0.92 | — | — | |
| SCHEMBL737602 | 0.90 | L3MBTL3 (0.31) | L3MBTL3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2103 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024123102-A1 | NOVEL TRICYCLIC COMPOUND AS KRAS G12D INHIBITOR, AND USE THEREOF | 에스케이바이오팜 주식회사 | 2024-06-13 | — | — | WO | claimed |
| US-20230114064-A1 | NOVEL HETEROAROMATIC SILICON-FLUORIDE-ACCEPTORS USEFUL FOR 18F LABELING OF MOLECULES AND BIOMOLECULES, AND METHODS OF PREPARING SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-04-13 | — | — | US | claimed |
| EP-3303349-B1 | NOVEL HETEROAROMATIC SILICON-FLUORIDE-ACCEPTORS USEFUL FOR 18F LABELING OF MOLECULES AND BIOMOLECULES, AND METHODS OF PREPARING SAME | UNIV CALIFORNIA (US) | 2022-07-06 | — | — | EP | claimed |
| US-20200377529-A1 | NOVEL HETEROAROMATIC SILICON-FLUORIDE-ACCEPTORS USEFUL FOR 18F LABELING OF MOLECULES AND BIOMOLECULES, AND METHODS OF PREPARING SAME | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2020-12-03 | — | — | US | claimed |
| US-10800797-B2 | Heteroaromatic silicon-fluoride-acceptors useful for 18F labeling of molecules and biomolecules, and methods of preparing same | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2020-10-13 | — | — | US | claimed |
| US-10544188-B2 | Inhibitor of apoptosis protein (IAP) antagonists | Sanford Burnham Prebys Medical Discovery Institute (US) | 2020-01-28 | — | — | US | claimed |
| US-9546174-B2 | Inhibitor of apoptosis protein (IAP) antagonists | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2017-01-17 | — | — | US | claimed |
| WO-2016123709-A1 | FLUORINATED IMIDAZO[4,5-C]QUINOLINE DERIVATIVES AS INHIBITORS OF BROMODOMAIN CONTAINING PROTEINS | TRILLIUM THERAPEUTICS INC. (CA) | 2016-08-11 | — | — | WO | claimed |
| EP-1675855-B1 | 4-AMINO-QUINOLINE OUINOLIZIDINYL-AND QUINOLIZIDINYLALKYL-DERIVATIVES WITH ANTIMALARIAL ACTIVITY | NEED PHARMACEUTICALS S R L (IT) | 2008-12-10 | — | — | EP | claimed |
| US-20070219254-A1 | Therapeutic Compounds: Pyridine N-Oxide Scaffold | ASTRAZENECA AB (SE) | 2007-09-20 | — | — | US | claimed |
| US-5985926-A | VIRICIDES OF AMINE COMPOUNDS AND HYDROCARBONS | CELL THERAPEUTICS, INC. (US) | 1999-11-16 | — | — | US | claimed |
| US-5856331-A | LYSOPHOSPHATIDIC ACYLTRANSFERASE INHIBITOR | CELL THERAPEUTICS, INC. (US) | 1999-01-05 | — | — | US | claimed |
| US-5641783-A | ANTIINFLAMMATORY OR IMMUNOSUPPRESSIVE AGENTS | CELL THERAPEUTICS, INC. (US) | 1997-06-24 | — | — | US | claimed |
| EP-0739203-A1 | METHOD FOR TREATING DISEASES MEDIATED BY CELLULAR PROLIFERATION IN RESPONSE TO PDGF, EGF, FGF AND VEGF | CELL THERAPEUTICS, INC. (US) | 1996-10-30 | — | — | EP | claimed |
| EP-0728003-A1 | METHOD FOR PREVENTING TISSUE INJURY FROM HYPOXIA | CELL THERAPEUTICS, INC. (US) | 1996-08-28 | — | — | EP | claimed |
| EP-0676958-A1 | METHOD FOR INHIBITING INTRACELLULAR VIRAL REPLICATION | CELL THERAPEUTICS, INC. (US) | 1995-10-18 | — | — | EP | claimed |
| WO-1995019171-A1 | METHOD FOR TREATING DISEASES MEDIATED BY CELLULAR PROLIFERATION IN RESPONSE TO PDGF, EGF, FGF AND VEGF | CELL THERAPEUTICS, INC. (US) | 1995-07-20 | — | — | WO | claimed |
| WO-1995013075-A1 | METHOD FOR PREVENTING TISSUE INJURY FROM HYPOXIA | CELL THERAPEUTICS, INC. (US) | 1995-05-18 | — | — | WO | claimed |
| WO-1995012396-A1 | METHOD FOR INHIBITING INTRACELLULAR VIRAL REPLICATION | CELL THERAPEUTICS, INC. (US) | 1995-05-11 | — | — | WO | claimed |
| US-4877795-A | 4H-quinolizin-4-one compounds useful for the treatment of allergic bronchial asthma, allergic rhinitis atropic dermatitis and the like | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 1989-10-31 | — | — | US | claimed |